Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

医学 艾塞那肽 安慰剂 内科学 帕金森病 随机对照试验 物理疗法 临床试验 疾病 2型糖尿病 糖尿病 内分泌学 病理 替代医学
作者
Dilan Athauda,Kate Maclagan,Simon S. Skene,Martha Bajwa-Joseph,Dawn Letchford,Kashfia Chowdhury,Steve Hibbert,Natalia Budnik,Luca Zampedri,John Dickson,Yazhou Li,Icíar Avilés-Olmos,Thomas T. Warner,Patricia Limousin,Andrew J. Lees,Nigel H. Greig,Susan Tebbs,Thomas Foltynie
出处
期刊:The Lancet [Elsevier BV]
卷期号:390 (10103): 1664-1675 被引量:768
标识
DOI:10.1016/s0140-6736(17)31585-4
摘要

Background Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has neuroprotective effects in preclinical models of Parkinson's disease. We investigated whether these effects would be apparent in a clinical trial. Methods In this single-centre, randomised, double-blind, placebo-controlled trial, patients with moderate Parkinson's disease were randomly assigned (1:1) to receive subcutaneous injections of exenatide 2 mg or placebo once weekly for 48 weeks in addition to their regular medication, followed by a 12-week washout period. Eligible patients were aged 25–75 years, had idiopathic Parkinson's disease as measured by Queen Square Brain Bank criteria, were on dopaminergic treatment with wearing-off effects, and were at Hoehn and Yahr stage 2·5 or less when on treatment. Randomisation was by web-based randomisation with a two strata block design according to disease severity. Patients and investigators were masked to treatment allocation. The primary outcome was the adjusted difference in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor subscale (part 3) in the practically defined off-medication state at 60 weeks. All efficacy analyses were based on a modified intention-to-treat principle, which included all patients who completed any post-randomisation follow-up assessments. The study is registered at ClinicalTrials.gov (NCT01971242) and is completed. Findings Between June 18, 2014, and March 13, 2015, 62 patients were enrolled and randomly assigned, 32 to exenatide and 30 to placebo. Our primary analysis included 31 patients in the exenatide group and 29 patients in the placebo group. At 60 weeks, off-medication scores on part 3 of the MDS-UPDRS had improved by 1·0 points (95% CI −2·6 to 0·7) in the exenatide group and worsened by 2·1 points (−0·6 to 4·8) in the placebo group, an adjusted mean difference of −3·5 points (−6·7 to −0·3; p=0·0318). Injection site reactions and gastrointestinal symptoms were common adverse events in both groups. Six serious adverse events occurred in the exenatide group and two in the placebo group, although none in either group were judged to be related to the study interventions. Interpretation Exenatide had positive effects on practically defined off-medication motor scores in Parkinson's disease, which were sustained beyond the period of exposure. Whether exenatide affects the underlying disease pathophysiology or simply induces long-lasting symptomatic effects is uncertain. Exenatide represents a major new avenue for investigation in Parkinson's disease, and effects on everyday symptoms should be examined in longer-term trials. Funding Michael J Fox Foundation for Parkinson's Research.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
4秒前
面包恐龙完成签到,获得积分10
4秒前
4秒前
RolfHoward完成签到,获得积分10
4秒前
4秒前
小赵爱漂亮完成签到 ,获得积分10
5秒前
羊_完成签到,获得积分10
5秒前
7秒前
傻子发布了新的文献求助20
8秒前
8秒前
8秒前
Twinkle发布了新的文献求助10
9秒前
SciGPT的应助被威武的皮卡丘采纳,获得10
9秒前
秋风的应助被Linkkk采纳,获得10
9秒前
10秒前
完美世界的应助被科研通管家采纳,获得10
10秒前
yang完成签到 ,获得积分10
10秒前
CarryLJR的应助被科研通管家采纳,获得10
10秒前
10秒前
Hello的应助被科研通管家采纳,获得10
10秒前
DW的应助被科研通管家采纳,获得10
10秒前
酷波er的应助被科研通管家采纳,获得10
10秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
10秒前
今后的应助被科研通管家采纳,获得10
10秒前
n01W97的应助被科研通管家采纳,获得20
11秒前
11秒前
Maestro_S的应助被科研通管家采纳,获得10
11秒前
传奇3的应助被科研通管家采纳,获得10
11秒前
江就的应助被科研通管家采纳,获得10
11秒前
11秒前
李爱国的应助被科研通管家采纳,获得10
11秒前
11秒前
11秒前
我是老大的应助被科研通管家采纳,获得10
11秒前
科目三的应助被科研通管家采纳,获得10
11秒前
传奇3的应助被科研通管家采纳,获得10
12秒前
12秒前
13秒前
MAX发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189382
求助须知:如何正确求助?哪些是违规求助? 9576691
关于积分的说明 21849410
捐赠科研通 7787318
什么是DOI,文献DOI怎么找? 3435538
关于科研通互助平台的介绍 2559748
邀请新用户注册赠送积分活动 2482509